|Grant Affiliation:||Haynes: B-Cell Lineage Envelope Design|
|Strategy:||Prophylactic neutralizing Ab|
|Study Type:||Antibody Screening|
|Study Start Date:||2014-05-27|
|Study Made Public:||2016-11-01|
Impact of IgG Subclass on Capacity to Mediate Neutralization of TH023.6
CAVD 454 is an immunogenicity study to characterize the neutralization of monoclonal antibodies from RV144 human clinical trial vaccine recipients.
Sign in to see full information about this study and to download study data.